• by bcarlson@marketresearch.com
  • May 26 2016


Medical Devices: Growth Through Acquisitions, US Sales and R&D

Medical Devices: Growth Through Acquisitions, US Sales and R&D

Even with slight growth in the market, prospects in medical devices are promising for many firms. More promising than, for example, in the pharmaceutical industry, challenged by patent expirations and regulatory activity. Innovators can still win. This is the finding of Kalorama Information’s yearly study of medical devices. While the majority of medtech sales occur outside the U.S., the United States remains the single largest country market and in 2015 firms found increased sales there as Euro...


At a Crossroads, Pharma Clients Seek Flexibility, Efficiency in CRO Market

At a Crossroads, Pharma Clients Seek Flexibility, Efficiency in CRO Market

Kalorama Information also offers the report Proteomics Research Markets: Instruments (Mass Spectrometry, Liquid Chromatography, Electrophoresis), Disease Areas (Oncology, Cardio/Blood, Neurology, Other) Market Share and Trends for market insights into selected products used in biomarker and drug discovery research.

Tracked through seven editions of Kalorama Information’s Outsourcing in Drug Discovery , pharmaceutical research and development (R&D) is now pinned between building market pressure...


Blood Screening Leads Revival of China’s National Blood Program

Blood Screening Leads Revival of China’s National Blood Program

Investment in screening diagnostics is pivotal in China’s effort to strengthen its scandal-bitten national blood program. Kalorama Information’s recently published Blood Testing Market in China provides IVD-relevant insights into both regional and national demand for blood screening products in China. Blood supply in China is insufficient today to meeting clinical demand in China, but increased donation is being encouraged as blood centers update screening standards and works to improve transfus...


Cepheid, Others Look Beyond Respiratory Infections in the Molecular POC Diagnostics Market

Companies looking beyond the clinical lab in the molecular diagnostics market predominately target rapid test demand in primary care and critical care, chiefly respiratory infections. All CLIA waivers to date for molecular tests have been for respiratory infections (influenza, strep A, RSV), though equally ample and more promising markets for molecular point-of-care (POC) diagnostics market will be found in other areas - including women’s health/sexual health and high-burden diseases in the deve...